Literature DB >> 31428862

Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Parita Shah1,2, Yusuke Iwata1,3, Eric E Brown1,2,3,4, Julia Kim1,2, Marcos Sanches5,6, Hiroyoshi Takeuchi7, Shinichiro Nakajima1,7, Margaret Hahn2,3,8,9, Gary Remington2,3,4,8, Philip Gerretsen1,2,3,4,8, Ariel Graff-Guerrero10,11,12,13,14.   

Abstract

Although clozapine is the main antipsychotic medication for treatment-resistant schizophrenia, 40-70% of patients on clozapine have persistent psychotic symptoms (i.e. ultra-treatment-resistant schizophrenia, UTRS). We aimed to examine clozapine response/non-response patterns in patients with treatment-resistant schizophrenia, as well as determine patient clinico-demographic factors associated with long-term clozapine non-response. Clinico-demographic characteristics of 241 patients on clozapine were collected through a retrospective chart review. The median (interquartile range, IQR) follow-up from illness onset was 25.0 (IQR = 24.0) years. Clozapine response was assessed at median 10.8 (IQR = 14.0) months (Time 1, T1) and 7.2 (IQR = 13.5) years (Time 2, T2) after its initiation. It was evaluated by chart reviewers based on the information provided in clinical notes. Binomial logistic regression was used to determine clinico-demographic factors associated with clozapine non-response at both T1 and T2 (i.e. stable UTRS, S-UTRS) compared to clozapine response at both times (i.e. stable clozapine responders, S-ClozResp). Among clozapine responders (n = 122) at T1, 83.6% remained clozapine responsive and 16.4% became non-responsive at T2. In the UTRS group (n = 119) at T1, 87.4% remained clozapine non-responsive and 12.6% became responsive at T2. Duration of delay in clozapine initiation (OR = 0.94, Wald χ2 = 5.33, p = 0.021) and number of pre-clozapine hospitalizations (OR = 0.95, Wald χ2 = 5.20, p = 0.023) were associated with S-UTRS. Most UTRS patients were non-responsive to clozapine from the start of treatment. Preventing delay in initiating clozapine and relapses could help promote long-term clozapine response in patients with treatment-resistant schizophrenia. Future longitudinal studies are required to explore the neuropathological correlates of relapses and delay in clozapine initiation.

Entities:  

Keywords:  Clozaril; Outcome; Psychosis; Response; Schizophrenia; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31428862     DOI: 10.1007/s00406-019-01053-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  73 in total

1.  Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

Authors:  Umit B Semiz; Mesut Cetin; Cengiz Basoglu; Servet Ebrinc; Ozcan Uzun; Hasan Herken; Hakan Balibey; Ayhan Algul; Alpay Ates
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-06-12       Impact factor: 5.067

Review 2.  The neurobiology of relapse in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid; Gagan Fervaha; Hiroyoshi Takeuchi; Margaret Hahn
Journal:  Schizophr Res       Date:  2013-10-24       Impact factor: 4.939

Review 3.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

Review 4.  Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology.

Authors:  A Carlo Altamura; Sara Pozzoli; Alessio Fiorentini; Bernardo Dell'osso
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-09-25       Impact factor: 5.067

5.  Clozapine use in early psychosis.

Authors:  Kristen Thien; Meghan Bowtell; Scott Eaton; Melissa Bardell-Williams; Linglee Downey; Aswin Ratheesh; Patrick McGorry; Brian O'Donoghue
Journal:  Schizophr Res       Date:  2018-03-08       Impact factor: 4.939

Review 6.  Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

Authors:  Dilip V Jeste; Owen M Wolkowitz; Barton W Palmer
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

7.  Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

Authors:  Antonio Ciapparelli; Liliana Dell'Osso; Adolfo Bandettini di Poggio; Claudia Carmassi; Donatella Cecconi; Melania Fenzi; Maria C Chiavacci; Matteo Bottai; Carla E Ramacciotti; Giovanni B Cassano
Journal:  J Clin Psychiatry       Date:  2003-04       Impact factor: 4.384

8.  Changes in cortical thickness during the course of illness in schizophrenia.

Authors:  Neeltje E M van Haren; Hugo G Schnack; Wiepke Cahn; Martijn P van den Heuvel; Claude Lepage; Louis Collins; Alan C Evans; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2011-09

9.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

Review 10.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

View more
  10 in total

Review 1.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

2.  Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.

Authors:  Deepak K Sarpal; Annie Blazer; James D Wilson; Finnegan J Calabro; William Foran; Charles E Kahn; Beatriz Luna; K N Roy Chengappa
Journal:  Schizophr Res       Date:  2022-04-02       Impact factor: 4.662

3.  Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.

Authors:  Antonio F Pardiñas; Sophie E Smart; Isabella R Willcocks; Peter A Holmans; Charlotte A Dennison; Amy J Lynham; Sophie E Legge; Bernhard T Baune; Tim B Bigdeli; Murray J Cairns; Aiden Corvin; Ayman H Fanous; Josef Frank; Brian Kelly; Andrew McQuillin; Ingrid Melle; Preben B Mortensen; Bryan J Mowry; Carlos N Pato; Sathish Periyasamy; Marcella Rietschel; Dan Rujescu; Carmen Simonsen; David St Clair; Paul Tooney; Jing Qin Wu; Ole A Andreassen; Kaarina Kowalec; Patrick F Sullivan; Robin M Murray; Michael J Owen; James H MacCabe; Michael C O'Donovan; James T R Walters; Olesya Ajnakina; Luis Alameda; Thomas R E Barnes; Domenico Berardi; Elena Bonora; Sara Camporesi; Martine Cleusix; Philippe Conus; Benedicto Crespo-Facorro; Giuseppe D'Andrea; Arsime Demjaha; Kim Q Do; Gillian A Doody; Chin B Eap; Aziz Ferchiou; Marta Di Forti; Lorenzo Guidi; Lina Homman; Raoul Jenni; Eileen M Joyce; Laura Kassoumeri; Inès Khadimallah; Ornella Lastrina; Roberto Muratori; Handan Noyan; Francis A O'Neill; Baptiste Pignon; Romeo Restellini; Jean-Romain Richard; Franck Schürhoff; Filip Španiel; Andrei Szöke; Ilaria Tarricone; Andrea Tortelli; Alp Üçok; Javier Vázquez-Bourgon
Journal:  JAMA Psychiatry       Date:  2022-03-01       Impact factor: 25.911

4.  Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.

Authors:  Sherry Kit Wa Chan; Hei Yan Veronica Chan; William G Honer; Tarun Bastiampillai; Yi Nam Suen; Wai Song Yeung; Ming Lam; Wing King Lee; Roger Man King Ng; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

5.  Possible pharmacogenetic factors in clozapine treatment failure: a case report.

Authors:  Eromona Whiskey; Graziella Romano; Matilda Elliott; Malcolm Campbell; Cholan Anandarajah; David Taylor; Koravangattu Valsraj
Journal:  Ther Adv Psychopharmacol       Date:  2021-07-22

6.  An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s.

Authors:  Jose de Leon; Georgios Schoretsanitis; Can-Jun Ruan; Carlos De Las Cuevas; John M Kane; Christoph U Correll
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06       Impact factor: 5.760

7.  Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine.

Authors:  Daniela Fonseca de Freitas; Giouliana Kadra-Scalzo; Deborah Agbedjro; Emma Francis; Isobel Ridler; Megan Pritchard; Hitesh Shetty; Aviv Segev; Cecilia Casetta; Sophie E Smart; Johnny Downs; Søren Rahn Christensen; Nikolaj Bak; Bruce J Kinon; Daniel Stahl; James H MacCabe; Richard D Hayes
Journal:  J Psychopharmacol       Date:  2022-02-25       Impact factor: 4.562

8.  Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.

Authors:  Farhana Islam; Daniel Hain; David Lewis; Rebecca Law; Lisa C Brown; Julie-Anne Tanner; Daniel J Müller
Journal:  Pharmacogenomics J       Date:  2022-06-16       Impact factor: 3.245

9.  A predictor model of treatment resistance in schizophrenia using data from electronic health records.

Authors:  Giouliana Kadra-Scalzo; Daniela Fonseca de Freitas; Deborah Agbedjro; Emma Francis; Isobel Ridler; Megan Pritchard; Hitesh Shetty; Aviv Segev; Cecilia Casetta; Sophie E Smart; Anna Morris; Johnny Downs; Søren Rahn Christensen; Nikolaj Bak; Bruce J Kinon; Daniel Stahl; Richard D Hayes; James H MacCabe
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

10.  Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil.

Authors:  Douglas de Sousa Soares; Danyelle Rolim Carvalho; Mellanie Dellylah Trinta Ribeiro; Elton Jorge Bessa Diniz; Alcides Ferreira Rêgo
Journal:  Trends Psychiatry Psychother       Date:  2021-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.